The good news for #Grail is that the #FDA's panel of external experts voted in favour of its #Galleritest for multiple cancers at a meeting yesterday. The bad news is that the discussions revealed some had misgivings about the #bloodtest – even if they voted for it.
@pharmaphorum.bsky.social